Analysis of serum UBE2E3-Ab levels of HDs versus those of patients with chronic kidney disease (CKD)
Sample information and alpha analysis
(A) Sample information
HD
Type-1 CKD
Type-2 CKD
Type-3 CKD
Total sample number
82
145
32
123
Male/Female
44/38
106/39
21/11
70/53
Age (average ± SD)
44.1 ± 11.2
66.0 ± 10.4
76.0 ± 9.8
62.0 ± 11.7
(B) Alpha analysis (antibody level)
UBE2E3-Ab
HD
Average
1,625
SD
1,403
Cutoff value
4,432
Positive No.
2
Positive rate (%)
2.4%
Type 1-CKD
Average
3,404
SD
2,348
Positive No.
25
Positive rate (%)
17.2%
P (vs. HD)
1.3E-11
Type 2-CKD
Average
3,177
SD
1,409
Positive No.
5
Positive rate (%)
15.6%
P (vs. HD)
2.1E-06
Type 3-CKD
Average
2,602
SD
1,381
Positive No.
10
Positive rate (%)
8.1%
P (vs. HD)
2.1E-06
Type-1, -2, and -3 CKDs correspond to diabetic kidney disease, nephrosclerosis, and glomerulonephritis, respectively. The upper panel (A) indicates the numbers of all samples and samples from males and females, as well as age (average ± SD). The lower panel (B) summarizes the serum antibody levels examined by AlphaLISA using purified UBE2E3-GST protein as an antigen, as described in the legend of Table 1. P values were calculated using the Kruskal–Wallis test (Mann–Whitney U test with Bonferroni correction applied). P values < 0.05 and positive rates > 10% are marked in bold text. A scatter dot plot of the same results is shown in Figure 2D
The authors would like to thank Prof. Masaki Takiguchi (Chiba University), Prof. Kenichiro Kitamura (Yamanishi University), Prof. Hao Wang (Jinan University), Dr. Xiao-Meng Zhang (Chiba University), Dr. Mari Oba (National Center of Neurology and Psychiatry, Tokyo), Dr. Risa Kimura (Chiba University), for supporting this research as well as Ms. Seiko Otsuka, Masae Suzuki, Chiho Kusaka, Satoko Ishibashi, and Akiko Kimura for technical assistance.
The authors declare that they have no conflicts of interest.
Ethical approval
This study was approved by the Local Ethical Review Board of Chiba University, Graduate School of Medicine [approved numbers: 2012-438, 2014-44, 2016-86, 2017-251, 2018-320, 2020-1129, 2022-623, 2023-836], Toho University, Faculty of Medicine [approved numbers: A18103_A17052_A16035_A16001_26095_25024_ 24038_22047, 25131_23005], Toho University Omori Medical Center [approved number: 26-255], and Port Square Kashiwado Clinic [approved number: 2012‑001] as well as by the review boards of the participating hospitals. All experimental procedures were performed in accordance with the Declaration of Helsinki, version 2013.
Consent to participate
Written informed consent was obtained from all participants by following the protocols approved by their institutional ethical committees.
This work was supported, in part, by research grants from the Japan Science and Technology Agency [JST: Exploratory Research No. 14657335], Japan Science and Technology Agency SPRING [grant nos. JPMJSP2109], and research grants from Japan Society for the Promotion of Science KAKENHI [Grant Number: 20K17953, 22K07273, 20K07810, 21K19437, 21K08695, 16K10520]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Kikuchi Y, Shimada H, Yamasaki F, Yamashita T, Araki K, Horimoto K, et al. Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2.Int J Clin Oncol. 2024;29:512–34. [DOI] [PubMed]
Nakashima K, Shimada H, Ochiai T, Kuboshima M, Kuroiwa N, Okazumi S, et al. Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma.Int J Cancer. 2004;112:1029–35. [DOI] [PubMed]
Kuboshima M, Shimada H, Liu T, Nakashima K, Nomura F, Takiguchi M, et al. Identification of a novel SEREX antigen, SLC2A1/GLUT1, in esophageal squamous cell carcinoma.Int J Oncol. 2006;28:463–8. [PubMed]
Hou J, Zhao R, Xia W, Chang C, You Y, Hsu J, et al. PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis.Nat Cell Biol. 2020;22:1264–75. [DOI] [PubMed] [PMC]
Routsias JG, Tzioufas AG. Autoimmune response and target autoantigens in Sjogren’s syndrome.Eur J Clin Invest. 2010;40:1026–36. [DOI] [PubMed]
Fularski P, Czarnik W, Dąbek B, Lisińska W, Radzioch E, Witkowska A, et al. Broader Perspective on Atherosclerosis-Selected Risk Factors, Biomarkers, and Therapeutic Approach.Int J Mol Sci. 2024;25:5212. [DOI] [PubMed] [PMC]
Hiwasa T, Machida T, Zhang XM, Kimura R, Wang H, Iwase K, et al. Elevated levels of autoantibodies against ATP2B4 and BMP-1 in sera of patients with atherosclerosis-related diseases.Immunome Res. 2015;11:097. [DOI]
Hiwasa T, Tomiyoshi G, Nakamura R, Shinmen N, Kuroda H, Kunimatsu M, et al. Serum SH3BP5-specific antibody level is a biomarker of atherosclerosis.Immunome Res. 2017;13:132. [DOI]
Li S, Yoshida Y, Kobayashi E, Kubota M, Matsutani T, Mine S, et al. Serum anti-AP3D1 antibodies are risk factors for acute ischemic stroke related with atherosclerosis.Sci Rep. 2021;11:13450. [DOI] [PubMed] [PMC]
Hiwasa T, Yoshida Y, Kubota M, Li S, Zhang B, Matsutani T, et al. Serum antiKIAA0513 antibody as a common biomarker for mortal atherosclerotic and cancerous diseases.Med Int (Lond). 2024;4:45. [DOI] [PubMed] [PMC]
Makrilia N, Lappa T, Xyla V, Nikolaidis I, Syrigos K. The role of angiogenesis in solid tumours: an overview.Eur J Intern Med. 2009;20:663–71. [DOI] [PubMed]
Tapia-Vieyra JV, Delgado-Coello B, Mas-Oliva J. Atherosclerosis and Cancer; A Resemblance with Far-reaching Implications.Arch Med Res. 2017;48:12–26. [DOI] [PubMed]
Hiwasa T, Wang H, Goto K, Mine S, Machida T, Kobayashi E, et al. Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke.BMC Med. 2021;19:131. [DOI] [PubMed] [PMC]
Nishiura R, Fujimoto S, Sato Y, Yamada K, Hisanaga S, Hara S, et al. Elevated osteoprotegerin levels predict cardiovascular events in new hemodialysis patients.Am J Nephrol. 2009;29:257–63. [DOI] [PubMed]
Komatsu H, Fujimoto S, Hara S, Fukuda A, Fukudome K, Yamada K, et al. Recent therapeutic strategies improve renal outcome in patients with IgA nephropathy.Am J Nephrol. 2009;30:19–25. [DOI] [PubMed]
Goto K, Sugiyama T, Matsumura R, Zhang XM, Kimura R, Taira A, et al. Identification of cerebral infarction-specific antibody markers from autoantibodies detected in patients with systemic lupus erythematosus.J Mol Biomark Diagnos. 2015;6:2. [DOI]
Hamanaka S, Nakagawa T, Hiwasa T, Ohta Y, Kasamatsu S, Ishigami H, et al. Investigation of novel biomarkers for predicting the clinical course in patients with ulcerative colitis.J Gastroenterol Hepatol. 2018;33:1975–83. [DOI] [PubMed]
Naito A, Hiwasa T, Tanabe N, Sanada TJ, Sugiura T, Shigeta A, et al. Elevated levels of autoantibodies against EXD2 and PHAX in the sera of patients with chronic thromboembolic pulmonary hypertension.PLoS One. 2019;14:e0211377. [DOI] [PubMed] [PMC]
Vermeulen N, de Béeck KO, Vermeire S, Steen KV, Michiels G, Ballet V, et al. Identification of a novel autoantigen in inflammatory bowel disease by protein microarray.Inflamm Bowel Dis. 2011;17:1291–300. [DOI] [PubMed]
Chumpolkulwong N, Sakamoto K, Hayashi A, Iraha F, Shinya N, Matsuda N, et al. Translation of ‘rare’ codons in a cell-free protein synthesis system from Escherichia coli.J Struct Funct Genomics. 2006;7:31–6. [DOI] [PubMed]
Matsumura T, Terada J, Kinoshita T, Sakurai Y, Yahaba M, Tsushima K, et al. Circulating autoantibodies against neuroblastoma suppressor of tumorigenicity 1 (NBL1): A potential biomarker for coronary artery disease in patients with obstructive sleep apnea.PLoS One. 2018;13:e0195015. [DOI] [PubMed] [PMC]
Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.Clin Cancer Res. 2004;10:7252–9. [DOI] [PubMed]
Liu Y, Cai G, Chen P, Jiang T, Xia Z. UBE2E3 regulates cellular senescence and osteogenic differentiation of BMSCs during aging.PeerJ. 2021;9:e12253. [DOI] [PubMed] [PMC]
Sánchez-Duffhues G, Hiepen C, Knaus P, Dijke PT. Bone morphogenetic protein signaling in bone homeostasis.Bone. 2015;80:43–59. [DOI] [PubMed]
Tran LTT, Park H, Kim H. Is the carotid intima-media thickness really a good surrogate marker of atherosclerosis?J Atheroscler Thromb. 2012;19:680–90. [DOI] [PubMed]
Zureik M, Ducimetière P, Touboul PJ, Courbon D, Bonithon-Kopp C, Berr C, et al. Common carotid intima-media thickness predicts occurrence of carotid atherosclerotic plaques: longitudinal results from the Aging Vascular Study (EVA) study.Arterioscler Thromb Vasc Biol. 2000;20:1622–9. [DOI] [PubMed]
Shirai K, Utino J, Otsuka K, Takata M. A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI).J Atheroscler Thromb. 2006;13:101–7. [DOI] [PubMed]
Fan J, Watanabe T. Atherosclerosis: Known and unknown.Pathol Int. 2022;72:151–60. [DOI] [PubMed]
Nakamura R, Tomiyoshi G, Shinmen N, Kuroda H, Kudo T, Doi H, et al. An anti-deoxyhypusine synthase antibody as a marker of atherosclerosis-related cerebral infarction, myocardial infarction, diabetes mellitus, and chronic kidney disease.SM Atheroscler J. 2017;1:1001.
Sumazaki M, Shimada H, Ito M, Shiratori F, Kobayashi E, Yoshida Y, et al. Serum anti-LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseases.Cancer Sci. 2020;111:4453–64. [DOI] [PubMed] [PMC]
Li S, Yoshida Y, Kobayashi E, Adachi A, Hirono S, Matsutani T, et al. Association between serum antiASXL2 antibody levels and acute ischemic stroke, acute myocardial infarction, diabetes mellitus, chronic kidney disease and digestive organ cancer, and their possible association with atherosclerosis and hypertension.Int J Mol Med. 2020;46:1274–88. [DOI] [PubMed] [PMC]
Jarvandi S, Davidson NO, Schootman M. Increased risk of colorectal cancer in type 2 diabetes is independent of diet quality.PLoS One. 2013;8:e74616. [DOI] [PubMed] [PMC]
Fujihara S, Kato K, Morishita A, Iwama H, Nishioka T, Chiyo T, et al. Antidiabetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo.Int J Oncol. 2015;46:2172–80. [DOI] [PubMed]
Gallagher EJ, LeRoith D. Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality.Physiol Rev. 2015;95:727–48. [DOI] [PubMed] [PMC]
Goto A, Yamaji T, Sawada N, Momozawa Y, Kamatani Y, Kubo M, et al. Diabetes and cancer risk: A Mendelian randomization study.Int J Cancer. 2020;146:712–9. [DOI] [PubMed] [PMC]
Zhang C, Yang M. Functions of three ubiquitin-conjugating enzyme 2 genes in hepatocellular carcinoma diagnosis and prognosis.World J Hepatol. 2022;14:956–71. [DOI] [PubMed] [PMC]
Yang Y, Chang Y, Tsai K, Hung M, Kang B. UBE2C triggers HIF-1α-glycolytic flux in head and neck squamous cell carcinoma.J Cell Mol Med. 2022;26:3716–25. [DOI] [PubMed] [PMC]
Ma S, Chen Q, Li X, Fu J, Zhao L. UBE2C serves as a prognosis biomarker of uterine corpus endometrial carcinoma via promoting tumor migration and invasion.Sci Rep. 2023;13:16899. [DOI] [PubMed] [PMC]
Li S, Xue S, Li Z. Osteoporosis: Emerging targets on the classical signaling pathways of bone formation.Eur J Pharmacol. 2024;973:176574. [DOI] [PubMed]
Cai J, Pardali E, Sánchez-Duffhues G, Dijke Pt. BMP signaling in vascular diseases.FEBS Lett. 2012;586:1993–2002. [DOI] [PubMed]
Dyer LA, Pi X, Patterson C. The role of BMPs in endothelial cell function and dysfunction.Trends Endocrinol Metab. 2014;25:472–80. [DOI] [PubMed] [PMC]
Zhang M, Sara JD, Wang F, Liu L, Su L, Zhe J, et al. Increased plasma BMP-2 levels are associated with atherosclerosis burden and coronary calcification in type 2 diabetic patients.Cardiovasc Diabetol. 2015;14:64. [DOI] [PubMed] [PMC]
Sorescu GP, Sykes M, Weiss D, Platt MO, Saha A, Hwang J, et al. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress stimulates an inflammatory response.J Biol Chem. 2003;278:31128–35. [DOI] [PubMed]
Kim CW, Song H, Kumar S, Nam D, Kwon HS, Chang KH, et al. Anti-inflammatory and antiatherogenic role of BMP receptor II in endothelial cells.Arterioscler Thromb Vasc Biol. 2013;33:1350–9. [DOI] [PubMed] [PMC]
Yao Y, Bennett BJ, Wang X, Rosenfeld ME, Giachelli C, Lusis AJ, et al. Inhibition of bone morphogenetic proteins protects against atherosclerosis and vascular calcification.Circ Res. 2010;107:485–94. [DOI] [PubMed] [PMC]
Machida T, Kubota M, Kobayashi E, Iwadate Y, Saeki N, Yamaura A, et al. Identification of stroke-associated-antigens via screening of recombinant proteins from the human expression cDNA library (SEREX).J Transl Med. 2015;13:71. [DOI] [PubMed] [PMC]
Braig S, Bosserhoff A. Death inducer-obliterator 1 (Dido1) is a BMP target gene and promotes BMP-induced melanoma progression.Oncogene. 2013;32:837–48. [DOI] [PubMed]
Zhou W, Yan K, Xi Q. BMP signaling in cancer stemness and differentiation.Cell Regen. 2023;12:37. [DOI] [PubMed] [PMC]
Sharma T, Kapoor A, Mandal CC. Duality of bone morphogenetic proteins in cancer: A comprehensive analysis.J Cell Physiol. 2022;237:3127–63. [DOI] [PubMed]
Ehata S, Miyazono K. Bone Morphogenetic Protein Signaling in Cancer; Some Topics in the Recent 10 Years.Front Cell Dev Biol. 2022;10:883523. [DOI] [PubMed] [PMC]
Alkhathami AG, Abdullah MR, Ahmed M, Ahmed HH, Alwash SW, Mahdi ZM, et al. Bone morphogenetic protein (BMP)9 in cancer development: mechanistic, diagnostic, and therapeutic approaches?J Drug Target. 2023;31:714–24. [DOI] [PubMed]
